Integrate CEACAM5 IHC laboratory testing for treatment decisions in NSCLC patients
20 Dec 2022
Overexpression of CEACAM5 in NSCLC has elevated its potential as an actionable target. With upcoming availability of CEACAM5-targeted therapy, there is now a clinical need for testing of this biomarker and integration into the testing pathway of NSCLC patients.
To learn more about CEACAM5 IHC testing, register for the Lab Talk “The Importance of CEACAM5 Expression in NSCLC for Clinical Decision Making” to be held on DDMMYYY.
A recording of this session will be made available on DXRX post event.
